1 / 6

ESMO 2011 Lung Cancer AVAPERL Study

ESMO 2011 Lung Cancer AVAPERL Study. Authors : Dr. Sunil V erma Date posted: September 28 th , 2011. AVAPERL. Background: There is evidence for the use of bevacizumab in combination with chemotherapy in the first line treatment of advanced non-small cell lung cancer.

nansen
Download Presentation

ESMO 2011 Lung Cancer AVAPERL Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28th, 2011

  2. AVAPERL • Background: There is evidence for the use of bevacizumab in combination with chemotherapy in the first line treatment of advanced non-small cell lung cancer. Cisplatinand Pemetrexed has previously been shown to be associated with superior overall survival compared to Cisplatin and Gemcitabine in patients with non-squamous non small cell lung cancer. This study was designed to evaluate the benefit of maintenance pemetrexed in addition to bevacizumab compared to bevacizumab alone in patients who have received induction therapy with Cisplatin+Pemetrexed and Bevacizumab. 

  3. AVAPERL N= 253 Primary Outcome: Progression Free Survival, assessed from the beginning of the first line chemo Treatment A: Bevacizumab and Pemetrexed R Treatment B: Bevacizumab Patient Population All patients received four cycles of treatment with Cisplatin + Bevaciuzmab + Pemetrexed and those who didn't progress after this induction treatment were randomized

  4. RESULTS Progression Free Survival, assessed from the beginning of the first line chemo, and after a median follow-up of 11.0 months

  5. AVAPERLKey Conclusion Maintenance pemetrexed in combination with bevacizumab is associated with improvement in progression free survival for patients who have had first line treatment with Cisplatin+Pemetrexed and Bevacizumab.

  6. BOTTOM LINE FOR MEDICAL ONCOLOGISTS • Improved outcomes in the setting of bevacizumab based induction and maintenance therapy • Confirms the benefit  seen from the PARAMONT pemetrexed maintenance study • The data that we have to date for continued maintenance strategy (i.e. continuing one of the agents used in induction therapy) has only shows improvement in progression free survival, so we need to make sure that such an improvement is clinically meaningful and cost-effective- the cost-effectiveness of such a strategy needs to evaluated and studied further • Should the control arm been pemetrexed alone as there is more single agent activity associated with this agent

More Related